13 results about "TRPV1" patented technology

The present application relates to the technical field of asiatic acid, and particularly relates to an asiatic acid derivative and a preparation method.The asiatic acid derivative provided by the present application has R which is a straight chain or a branched chain with 1-24 carbon atoms, or a saturated or unsaturated monohydric alcohol alkyl formed by removing a hydroxyl group.The R group of the asiatic acid derivative of the present application has higher water solubility and oil solubility, especially oil solubility, so that the asiatic acid derivative has obviously enhanced liposolubility compared with asiatic acid, is easily dissolved in natural oil, alkane and other ester solvents, and has obviously enhanced biological activity, so that the asiatic acid derivative of the present application has high availability, improves the inhibition effect of the asiatic acid derivative on EDNRA and TRPV1, and further improves the anti-tumor effect, and the asiatic acid derivative has no safety risk.

This application relates to the field of molecular biology, and in particular to a screening method for TRPV1 agonists and its application. The provided screening method includes: obtaining transcriptome gene sequences from the coral *Dipsastraea rotumana* for functional annotation analysis, followed by classification to obtain transcriptome data; performing sequence alignment and phylogenetic tree construction on the transcriptome data to identify polypeptide sequences highly homologous to existing TRPV1 agonists; performing three-dimensional modeling of the polypeptide sequences to obtain the polypeptide 3D structure; and sequentially performing molecular docking and molecular dynamics analysis on the polypeptide 3D structure and the TRPV1-3D structure to screen for TRPV1 agonists. This method is highly efficient and low-cost, with high efficiency and accuracy; it facilitates the application of TRPV1 agonists in the preparation of products for treating neuroinflammation, providing new ideas and solutions for the treatment of neurodegenerative diseases.

This invention provides the application of a cyclic dipeptide in inhibiting the TRPV1 protein, wherein the cyclic dipeptide is a cyclic (D-leucine-L-proline) dipeptide. This invention also relates to the application of the cyclic dipeptide in the preparation of topical skin agents or pharmaceuticals with TRPV1 protein inhibitory activity, wherein the topical skin agent is selected from: creams, lotions, gels, toners, serums, masks, eye creams, aerosol cleansing foams, sprays, shower gels, or facial cleansers.

This TRPA1 activity inhibitor is characterized by containing glycyrrhizic acid or a salt thereof as an active ingredient. This TRPV1 activity inhibitor is characterized by containing glycyrrhizic acid or a salt thereof as an active ingredient. By using glycyrrhizic acid or a salt thereof as an active ingredient, a TRPA1 activity inhibitor and a TRPV1 activity inhibitor with excellent action and effect can be provided.

The application relates to the cosmetic technical field, and particularly discloses a water-oil balance composition suitable for sensitive skin and application thereof. The components in a suitable mass ratio range are matched with each other, so that the temperature-sensitive receptors of the skin can be synergistically regulated, natural moisturizing production is promoted, and ultraviolet protection is improved. The water-oil balance composition can selectively inhibit TRPV1-mediated 5alpha-reductase activity and ultraviolet-induced oxidative stress under high temperature in summer, accurately regulate sebum secretion without damaging the barrier, and promote the generation of natural moisturizing factors by activating filaggrin degradation in a low-temperature environment in winter, dynamically adjust the hydration degree of the stratum corneum, break through the technical limitations of traditional products, such as seasonal use and single and one-sided functions of active ingredients, realize cross-seasonal balanced care of a single formula, and are mild and non-irritating, and are suitable for sensitive skin.

Provided herein are methods of stabilizing blood pressure in severe sepsis / septic shock and other types of distributive shock using TRPV1 agonists. Also provided are pharmaceutical formulations for increasing blood pressure in septic shock the formulation including at least one TRPV1 agonist in a dosage form for parenteral administration, wherein the TRPV1 agonist is selected from capsaicin, daphnane TRPV1 agonists, vanillotoxin, N-oleoyl dopamine, N-arachidonyl dopamine, BrP-LPA, and derivatives and analogues thereof. Also provided are TRPV1 agonists co-lyophilized with adrenergic agonists and / or angiotensins in a dosage form for reconstitution and parenteral administration.

The present application relates to the technical field of asiatic acid, and particularly relates to an asiatic acid derivative and a preparation method. The asiatic acid derivative provided by the present application has R which is an alkyl group formed by removing a hydroxyl group from a saturated or unsaturated monohydric alcohol, and the saturated or unsaturated monohydric alcohol includes one of ethanol, octanol, hexadecanol, stearyl alcohol, 2-hexyl-1-decanol, decyltetradecin, oleyl alcohol, cis,cis-9,12-octadecadienol and bisabolol. The asiatic acid derivative of the present application has higher water solubility and oil solubility, especially oil solubility, so that the asiatic acid derivative has obviously enhanced liposolubility, is easily soluble in natural oil, alkane and other ester solvents, and has a significant inhibitory effect on EDNRA and TRPV1 and obviously enhanced bioactivity. The asiatic acid derivative of the present application has high availability, and the asiatic acid derivative has no safety risk.

The application provides a recombinant collagen IV and a preparation method and application thereof, and belongs to the technical field of bioengineering; based on part of active amino acid sequences in a natural human collagen IV alpha 5 chain as a basic monomer, a recombinant collagen IV sequence with repair and soothing effects is designed, and a recombinant expression vector is provided based on this, and a recombinant engineering bacterium is constructed; it is verified through experiments that the recombinant collagen IV can improve TGM1 expression, reduce TRPV1 expression, has cell adhesion activity and cell migration activity, the product has high HPLC purity, does not cause an immune response when applied to a human body, and has the value of being applied to the fields of cosmetics, medicines, health products, medical devices and biological materials.

The present application relates to the field of medicinal chemistry and pharmacotherapy, in particular to a phenylpiperazine compound or a pharmaceutically acceptable salt thereof, a preparation method and use thereof in the preparation of analgesic drugs or drugs for treating pain, wherein the phenylpiperazine compound or the pharmaceutically acceptable salt thereof has the following structure: the phenylpiperazine compound has obvious inhibitory activity on TRPV1, can obviously inhibit the pain response, and has no side effect of body temperature rise.

The present invention provides a new pharmaceutical composition and a method for treating and / or preventing social impairments such as autism spectrum disorder, fragile X syndrome, and / or autism spectrum disorder-like symptoms. Specifically, provided is a pharmaceutical composition for the treatment and / or prevention of social impairment, including a compound represented by Formula (I): wherein R1 is substituted or unsubstituted alkyl, R2 is a hydrogen atom or the like, A is N or the like, dashed lines indicate presence or absence of binding, R3 is substituted or unsubstituted alkyl or the like, m is 0 or 1, R4 and R5 are each independently a hydrogen atom or the like, or a pharmaceutically acceptable complex thereof.

Provided herein are methods of producing a population of pluripotent stem cell-derived sensory neurons (PSC-SNs) expressing a target gene associated with pain. In addition, provided herein are compositions and methods comprising populations of pluripotent stems cells for treating pain, osteoarthritis, and osteoarthritis related conditions.

This invention relates to the field of pharmaceutical technology, disclosing the application of *Melastoma candida* polysaccharide in the preparation of drugs for the prevention or treatment of chronic urticaria. This invention is the first to discover that *Melastoma candida* polysaccharide can regulate immune homeostasis, inhibit inflammatory responses, improve skin lesions, and restore intestinal flora balance through multiple pathways. It also inhibits the overactivation of the NGF / TRPV1 / p38 signaling pathway, reduces neurogenic inflammation and mast cell-mediated responses, thereby alleviating the pathological process of chronic urticaria. This broadens the application scope of *Melastoma candida* polysaccharide and provides a new approach for the treatment of allergic skin-related diseases.

The present invention provides a composition having an action to enhance adrenomedullin gene expression. One or more embodiments of the present invention relate to a composition for enhancing adrenomedullin gene expression containing a TRPV1 agonist and a TRPA1 agonist as active ingredients. The TRPV1 agonist can be, for example, at least one selected from capsaicin, 6-shogaol, 6-gingerol and piperine. The TRPA1 agonist can be, for example, at least one selected from allyl isothiocyanate, cinnamaldehyde, diallyl disulfide, ASP7663 and oxylipin.